OATP-J inhibitors are a class of chemical compounds designed to selectively inhibit the function of the organic anion-transporting polypeptide J (OATP-J), a member of the solute carrier organic anion transporter family. OATP-J is involved in the transmembrane transport of a wide variety of organic anions, including bile acids, hormones, and xenobiotics. OATP-J inhibitors act by binding to the transporter, thereby blocking the active site or preventing conformational changes necessary for substrate translocation. The inhibition of OATP-J can either be competitive, where the inhibitor directly competes with the substrate for the binding site, or non-competitive, where the inhibitor binds to an alternative site that indirectly impairs transporter function. The molecular design of these inhibitors often focuses on mimicking the structure of natural substrates to ensure effective interaction with the transporter while incorporating modifications that prevent their actual transport across the membrane.
The development of OATP-J inhibitors is guided by an in-depth understanding of the transporter's structure and binding characteristics. Structural studies using methods like cryo-electron microscopy (cryo-EM) and homology modeling provide detailed insights into the binding pocket and help identify key amino acid residues involved in substrate recognition. Computational approaches, such as molecular docking and quantitative structure-activity relationship (QSAR) modeling, are used to design and optimize inhibitors that exhibit high affinity and specificity for OATP-J. Chemical modifications, such as the introduction of bulky groups or altering the electronic properties of the core structure, are often employed to increase binding strength and specificity while preventing transport activity. OATP-J inhibitors can be diverse in chemical nature, including small organic molecules, peptidomimetics, or even macrocycles, depending on the mechanism of inhibition being targeted. Factors such as lipophilicity, stability, and membrane permeability are also carefully considered during the development process to ensure the effective interaction of these inhibitors with OATP-J in biological environments. The design and synthesis of OATP-J inhibitors require a thorough understanding of transporter mechanisms, structure-activity relationships (SAR), and the physiochemical properties that influence binding and efficacy.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporine A is known to inhibit several OATP family members, potentially affecting the transport activity of OATP-J. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $95.00 $322.00 $663.00 $1438.00 | 6 | |
Rifampicin can act as an inhibitor of certain OATP transporters, potentially influencing OATP-J related transport processes. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Atorvastatin, a commonly used statin, is known to interact with OATP transporters, which may include effects on OATP-J. | ||||||
Erythromycin | 114-07-8 | sc-204742 sc-204742A sc-204742B sc-204742C | 5 g 25 g 100 g 1 kg | $56.00 $240.00 $815.00 $1305.00 | 4 | |
Erythromycin, a macrolide antibiotic, has been reported to inhibit various OATP transporters, potentially affecting OATP-J. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $65.00 $262.00 | 2 | |
Gemfibrozil, a lipid-regulating agent, can inhibit OATP transporter activity, possibly influencing OATP-J. | ||||||
Indinavir | 150378-17-9 | sc-353630 | 100 mg | $982.00 | 1 | |
Indinavir, an antiretroviral drug, is known to interact with and inhibit certain OATP transporters, potentially affecting OATP-J. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, may influence OATP transporter activity, possibly affecting OATP-J. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $27.00 $38.00 $98.00 $272.00 | 28 | |
Probenecid, a uricosuric drug, is known to inhibit various transporters, including some OATP family members, potentially affecting OATP-J. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $76.00 $139.00 | 23 | |
Itraconazole, an antifungal agent, can inhibit OATP transporter activity, potentially influencing OATP-J. | ||||||
Fexofenadine | 83799-24-0 | sc-218475 | 100 mg | $292.00 | 1 | |
Fexofenadine, an antihistamine, has been shown to interact with OATP transporters, possibly affecting OATP-J. |